Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine

References

• Dillman RO, Nanci AA, Williams ST, Kim RB, Hafer RL, Coleman CL, Wang PC, Duma CM, Chen PV, Selvan SR, et al. Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine. Cancer Biother Radiopharm. 2010;25(5):553–57. PMID: 20849310. doi:10.1089/cbr.2010.0819.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Cornforth AN, McClay EF, Amatruda TT, Depriest C. Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in patients with metastatic melanoma: 5-year follow up and additional analyses. J ImmunoTher Cancer. 2018;6(1):19. PMID: 29510745. doi:10.1186/s40425-018-0330-1.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Cornforth AN, Depriest C, McClay EF, Amatruda TT, de Leon C, Ellis RE, Mayorga C, Carbonell D, Cubellis JM. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother. 2012;35(8):641–49. doi:10.1097/CJI.0b013e31826f79c8.
   PubMed Web of Science ®Google Scholar
• Thomas GP, Brown MA. Genetics and genomics of ankylosing spondylitis. Immunol Rev. 2010;233(1):162–80. PMID: 20192999. doi:10.1111/j.0105-2896.2009.00852.
   PubMedGoogle Scholar
• Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonazlez R, Weber JS, Gajewski TF, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182–90. PMID: 23775962. doi:10.1200/JCO.2012.47.7863.
   PubMed Web of Science ®Google Scholar
• Eklund KK, Niemi K, Kovanen PT. Immune functions of serum amyloid A. Crit Rev Immunol. 2012;32(4):335–48. PMID: 23237509. doi:10.1615/CritRevImmunol.v32.i4.
   PubMed Web of Science ®Google Scholar
• Cooper AM, Khader SA. Il-12p40: an inherently agonistic cytokine. Trends Immunol. 2007;28:33–38. doi:10.1016/j.it.2006.11.002.
   PubMed Web of Science ®Google Scholar
• Ling P, Gately MK, Gubler U, Stern AS, Lin P, Hollfelder K, Su C, Pan YC, Hakimi J. Human IL-12p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol. 1994;154(1):116–27. PMID: 7527811.
   Web of Science ®Google Scholar
• Klinke DJ 2nd. Monomer to dimer is an important determinant of IL-12 bioactivity. J Theor Biol. 2006;240(2):323–35. PMID: 16448670. doi:10.1016/j.jtbi.2005.09.022.
   PubMed Web of Science ®Google Scholar
• Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol. 2005;175(4):2261–69. PMID: 16081794. doi:10.4049/jimmunol.175.4.2261.
   PubMed Web of Science ®Google Scholar
• Davis MR, Zhu Z, Hansen DM, Bai Q, Fang Y. The role of IL-21 in immunity and cancer. Cancer Lett. 2015;358(2):107–14. PMID: 25575696. doi:10.1016/j.canlet.2014.12.047.
   PubMed Web of Science ®Google Scholar
• Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009;10(8):857–63. PMID: 19578369. doi:10.1038/ni.1767.
   PubMed Web of Science ®Google Scholar
• Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev. 2013;252(1):116–32. PMID: 23405899. doi:10.1111/imr.12027.
   PubMed Web of Science ®Google Scholar
• Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: immunobiology and patology. Ann Rev Immunol. 2015;33:747–85. PMID: 25706098. doi:10.1146/annurev-immunol-032414-112123.
   PubMed Web of Science ®Google Scholar
• Zenewicz LA. IL-22: there is a gap in our knowledge. ImmunoHorizons. 2018;2(6):198–207. PMID: 31022687. doi:10.4049/immunohorizons.1800006.
   PubMedGoogle Scholar
• Fioretti F, Fradelizi D, Stoppacciaro A, Ramponi S, Ruco L, Minty A, Sozzani S, Garlanda C, Vecchi A, Mantovani A. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protei-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J Immunol. 1998;161(1):342–46. PMID: 9647242.
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765. PMID: 11244051. doi:10.1146/annurev.immunol.19.1.683.
   PubMed Web of Science ®Google Scholar
• Oft M. IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol Res. 2014;2(3):194–99. PMID: 24778315. doi:10.1158/2326-6066.CIR-13-0214.
   PubMed Web of Science ®Google Scholar
• Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol. 2002;72(1):9–18. PMID: 12101257.
   PubMed Web of Science ®Google Scholar
• Cruikshank WW, Kornfeld H, Center DM. Interleukin-16. J Leukoc Biol. 2000;67(6):757–66. PMID: 10857846. doi:10.1002/jlb.2000.67.issue-6.
   PubMed Web of Science ®Google Scholar
• Ries C. Cytokine functions of TIMP-1. Cell Mol Life Sci. 2014;71(4):659–72. PMID: 23982756. doi:10.1007/s00018-013-1457-3.
   PubMed Web of Science ®Google Scholar
• Mehta AK, Gracias DT, Croft M. TNF activity and T cells. Cytokine. 2018;101:14–18. PMID: 27531077. doi:10.1016/j.cyto.2016.08.003.
   PubMed Web of Science ®Google Scholar
• Reina M, Espel E. Role of LFA-1 and ICAM-1 in cancer. Cancers (Basel). Nov 3 2017;9(11):E153. PMID: 29099772. doi: 10.3390/cancers9110153.
   PubMed Web of Science ®Google Scholar
• Broughton SE, Dhagat U, Hercus TR, Nero TL, Grimbaldeston MA, Bonder CS, Lopez AF, Parker MW. The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol Rev. 2012;250:277–302. PMID: 23046136. doi:10.1111/j.1600-065X.2012.01164.
   PubMed Web of Science ®Google Scholar
• Ghandi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–37. PMID: 28277826. doi:10.1080/1744666X.2017.1298443.
   PubMed Web of Science ®Google Scholar
• van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67(1):2–17. PMID: 10647992. doi:10.1002/jlb.2000.67.issue-1.
   PubMed Web of Science ®Google Scholar
• Elizondo DM, Andargie TE, Kubhar DS, Gugssa A, Lipscomb MW. CD40-CD40L cross-talk drives fascin expression in dendritic cells for efficient antigen presentation to CD4+ T cells. Int Immunol. 2017;29(3):121–31. PMID: 28369442. doi:10.1093/intimm/dxx013.
   PubMed Web of Science ®Google Scholar
• Frendl G. IL-3: from colony-stimulating factor to pluripotent immunoregulatory cytokine. Int J Immunopharmacol. 1992;14(3):421–30. PMID: 1618595. doi:10.1016/0192-0561(92)90172-H.
   PubMed Web of Science ®Google Scholar
• Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008;26:453–79. PMID: 18062768. doi:10.1146/annurev.immunol.26.021607.090357.
   PubMed Web of Science ®Google Scholar
• Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180–90. PMID: 22343569. doi:10.1038/nri3156.
   PubMed Web of Science ®Google Scholar
• Croxford AL, Mair F, Becher B. IL23: onecytokine in control of autoimmunity. Eur J Immunol. 2012;42(9):2263–73. PMID: 22949325. doi:10.1002/eji.201242598.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813–24. PMID: 17606980. doi:10.1093/intimm/dxm057.
   PubMed Web of Science ®Google Scholar
• Chamoto K, Al-Habsi M, Honjo T. Role of PD-1 in immunity and diseases. Curr Top Microbiol Immunol. 2017;410:75–97. PMID: 28929192. doi:10.1007/82201767.
   PubMed Web of Science ®Google Scholar
• Thijssen VL, Heusschen R, Caers J, Griffioen AW. Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochim Biophys Acta. 2015;1855(2):235–47. PMID: 25819524. doi:10.1016/j.bbcan.2015.03.003.
   PubMed Web of Science ®Google Scholar
• Colomb F, Wang W, Simpson D, Zafar M, Beynon R, Rhodes JM, Yu LG. Calectin-3 interacts with the cell-surface glycoprotein CD146 (MCAM, MUC18) and induces secretion of metastasis-promoting cytokines from vascular endothelial cells. J Biol Chem. 2017;292(20):8381–89. PMID: 28364041. doi:10.1074/jbc.M117.783431.
   PubMed Web of Science ®Google Scholar
• Esmailbeig M, Ghaderi A. Interleukin-18: a regulator of cancer and autoimmune diseases. Eur Cytokine Netw. 2017;28(4):l127–140. PMID: 29478963. doi:10.1684/ecn.2018.0401.
   PubMed Web of Science ®Google Scholar
• Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 2011;71(16):5393–5393. PMID: 21724589. doi:10.1158/0008-5472.CAN-11-0993.
   PubMed Web of Science ®Google Scholar
• Gaffen SL. An overview of IL-17 function and signaling. Cytokine. 2008;43(3):402–07. PMID:18701318. doi:10.1016/j.cyto.2008.07.017.
   PubMed Web of Science ®Google Scholar
• Zuniga LA, Jain R, Haines C, Cua DJ. Th17 cell development from cradle to grave. Immuno Rev. 2013;252(1):78–88. PMID: 23405896. doi:10.1111/imr.12036.
   PubMed Web of Science ®Google Scholar
• Llosa NJ, Geis AL, Thiele Orberg E, Housseau F. Interleukin-17 and type 17 helper T cells in cancer management and research 2014. Immunotargets Ther. 2014;10(3):39–54. eCollection 2014 PMID: 27471699. doi:10.2147/ITT.S56529.
   Google Scholar
• Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13(2):95–109. PMID: 11900986. doi:10.1016/S1359-6101(01)00038-7.
   PubMed Web of Science ®Google Scholar
• Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163–89. PMID: 14525967.
   PubMed Web of Science ®Google Scholar
• Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem. 1997;272(23):15036–42. PMID: 9169480. doi:10.1074/jbc.272.23.15036.
   PubMed Web of Science ®Google Scholar
• Achuthan A, Cook AD, Lee M-C, Saleh R, Khiew H-W, Chang MWN, Louis C, Fleetwood A, Lacey DC, Christensen AD, et al. Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation. J Clin Invest. 2016;126(9):3453–66. PMID 27525438. doi:10.1172/JCI87828.
   PubMed Web of Science ®Google Scholar
• Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, Harada A, Matsushima K, Kelvin DJ, Oppenheim JJ. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monoyctes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med. 1993;177(6):1808–14. PMID 8496693. doi:10.1084/jem.177.6.1809.
   Web of Science ®Google Scholar
• Gattass CR, King LB, Luster AD, Ashwell JD. Constitutive expression of interferon gamma-inducible protein 10 in lymphoid organs and inducible expression in T cells and thymocytes. J Exp Med. 1994;179(4):1373–78. PMID:8145049. doi:10.1084/jem.179.4.1373.
   PubMed Web of Science ®Google Scholar
• Silver JS, Hunter CA. gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol. 2010;88(6):1145–56. PMID: 20610800. doi:10.1189/jlb.0410217.
   PubMed Web of Science ®Google Scholar
• Wiguna AP, Walden P. Role of IL-10 and TGF-β in melanoma. Exp Dermatol. 2015;24(3):209–14. PMID: 25565012. doi:10.1111/exd.12629.
   PubMed Web of Science ®Google Scholar
• Jakowlew SB. Transforming growth factor-beta in cancer metastasis. Cancer Metastasis Rev. 2006;25(3):435–57. PMID: 16951986. doi:10.1007/s10555-006-9006-2.
   PubMed Web of Science ®Google Scholar
• Haque S, Morris JC. Transforming growth factor-β: a therapeutic target for cancer. Hum Vaccin Immunother. 2017;13(8):1741–50. PMID: 28575585. doi:10.1080/21645515.2017.1327107.
   PubMed Web of Science ®Google Scholar
• Xie J, Wang Y, Freeman ME 3rd, Barlogie B, Yi Q. Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood. 2003;101(10):4005–12. PMID: 12531797. doi:10.1182/blood-2002-11-3368.
   PubMed Web of Science ®Google Scholar
• Ogilvie P, Paoletti S, Clark-Lewis I, Uguccioni M. Eotaxin-3 is a natural antagonist for CCRT and experts a repulsive effect on human monocytes. Blood. 2003;102(3):789–94. PMID: 12689946. doi:10.1182/blood-2002-09-2773.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8–27. PMID: 29247995. doi:10.1111/imr.12621.
   PubMed Web of Science ®Google Scholar
• Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL/6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012;122(4):143–59. PMID: 22029668. doi:10.1042/CS20110340.
   PubMed Web of Science ®Google Scholar
• Taher MY, Davies DM, Maher J. The role of the interleukin (IL)-6/IL-6 receptor axis in cancer. Biochem Soc Trans. 2018;46(6):1449–62. PMID: 30467123. doi:10.1042/BST20180136.
   PubMedGoogle Scholar
• Jones BE, Maerz BJH. IL-6: a cytokine at the crossroads of autoimmunity. Curr Opin Immunol. 2018;55:9–14. PMID: 30248523. doi:10.1016/j.coi.2018.09.002.
   PubMed Web of Science ®Google Scholar
• Waugh DJJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14(21):8735–41. PMID: 18980965. doi:10.1158/1078-0432.CCR-07-4843.
   Web of Science ®Google Scholar
• Santana Carrero RM, Beceren-Braun F, Rivas SC, Hegde SM, Gangadharan A, Plote D, Pham G, SM A, Schluns KS. IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor responses. Proc Natl Acad Sci USA. 2019;116(2):599–608. PMID:30587590. doi:10.1073/pnas.1814642116.
   PubMed Web of Science ®Google Scholar
• Zhang M, Wen B, Anton OM, Yao Z, Dubois S, Ju W, Sato N, DiLillo DJ, Bamford RN, Ravetch JV, et al. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. Proc Natl Acad Sci. 2018;l115:E10915–E10924. doi:10.1073/pnas.1811615115.
   Google Scholar
• Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets. 2009;8(1):40–52. PMID: 19275692. doi:10.2174/187152809787582507.
   PubMedGoogle Scholar
• Lu X. Impact of IL-12 in cancer. Curr Cancer Drug Targets. 2017;17(8):682–97. PMID: 28460617. doi:10.2174/1568009617666170427102729.
   PubMed Web of Science ®Google Scholar
• Lyakh L, Trinchieri G, Provezza L, Carra G, Gerosa F. Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol Rev. 2008;226:112–31. doi:10.1111/imr.2008.226.issue-1.
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133–46. PMID: 19161420. doi:10.1111/j.1600-065X.2008.00700.
   PubMed Web of Science ®Google Scholar
• Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, Enk A, Steinman RM, Romani N, Schuler G. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol. 1996;26:659–68. PMID 8760828. doi:10.1002/eji.1830260323.
   PubMed Web of Science ®Google Scholar
• Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J, Kulig P, Becher B. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 2015;22:237–46. PMID:25190142. doi:10.1038/cdd.2014.134.
   PubMed Web of Science ®Google Scholar
• Ivanova M, Manolova I, Miteva L, Gancheva R, Stoilov R, Stanilova S. Genetic variations in the IL-12B gene in association with IL-23 and IL12p40 serum levels in ankylosing spondylitis. Rheumatol Int. 2019;39(1):111–19. PMID: 30443744. doi:10.1007/s00296-018-4204-0.
   PubMed Web of Science ®Google Scholar
• Dixon KO, O’Flynn J, van der Kooij SW, van Kooten C. Phagocytosis of apoptotic or necrotic cells differentially regulates the transcriptional expression of IL-12 family members in dendritic cell. J Leukoc Biol. 2014;96(2):313–24. PMID: 24782489. doi:10.1189/jlb.3A1013-538RR.
   PubMed Web of Science ®Google Scholar
• Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunol. 2008;123(3):326–28. PMID: 17983439. doi:10.1111/j.1365-2567.2007.02719.x.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265–77. PMID: 22437871. doi:10.1038/nrc3258.
   PubMed Web of Science ®Google Scholar
• Mellman I. Dendritic cells: master regulators of the immune response. Cancer Immunol Res. 2013;1(3):145–49. PMID: 24777676. doi:10.1158/2326-6066.CIR-13-0102.
   PubMed Web of Science ®Google Scholar
• Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12(8):557–69. PMID: 22790179. doi:10.1038/nri3254.
   PubMed Web of Science ®Google Scholar
• Van Endert P. Intracellular recycling and cross-presentation by MHC class I molecules. Immuno Rev. 2016;272(1):80–96. PMID: 27319344. doi:10.1111/imr.12424.
   PubMed Web of Science ®Google Scholar
• Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, Schreibelt G, Mus R, De Wilt JH, Haanen JB, et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell based vaccination. Cancer Res. 2013;73:19–29. PMID: 23087058. doi:10.1158/0008-5472.CAN-12-1127.
   PubMed Web of Science ®Google Scholar
• Chaudhry A, Rudra D, Treuting P, Samstein RM, Liang Y, Kas A, Rudensky AY. CD4+ regulatory T cells control Th17 responses in a Stat3-dependent manner. Science. 2009;326(5955):986–91. PMID: 19797626. doi:10.1126/science.1172702.
   PubMed Web of Science ®Google Scholar
• Wei S, Zhao E, Kryczek I, Zou W. Th17 cells have stem cell-like features and promote long-term immunity. Oncoimmunology. 2012;1(4):516–19. PMID: 22754771. doi:10.4161/onci.19440.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114(6):1141–49. PMID:19470694. doi:10.1182/blood-2009-03-208249.
   PubMed Web of Science ®Google Scholar
• Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF. Chemokine expression in melanoma metastases associated with CD8+T-cell recruitment. Cancer Res. 2009;69:3077–85. PMID: 19293190. doi:10.1158/0008-5472.CAN-08-2281.
   PubMed Web of Science ®Google Scholar
• Cannon MJ, Goyne SPJ, Chiriva-Internati M. Dendritic cell vaccination against ovarian cancer—tipping the Treg/Th17 balance to therapeutic advantage? Expert Opin Biol Ther. 2011;11(4):441–45. PMID: 21271951. doi:10.1517/14712598.2011.554812.
   PubMed Web of Science ®Google Scholar
• Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, et al. Tumor-specific Th-17-polarized cells eradicate large established melanoma. Blood. 2008;112(2):362–73. PMID: 18354038. doi:10.1182/blood-2007-11-120998.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhao Q, Wang G, Yang C, Xu Y, Li Y, Yang P. Circulating levels of Th1 and Th2 chemokines in patients with ankylosing spondylitis. Cytokine. 2016;81:10–14. PMID: 26827189. doi:10.1016/j.cyto.2016.01.012.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. PMID:2137623. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Turner N, Ware O, Bosenberg M Genetics of metastasis: melanoma and other cancers. Clin Exp Metastasis. 2018 Aug;35(5–6):379–91. PMID: 29722002. doi:10.1007/s10585-018-9893-y.
   PubMed Web of Science ®Google Scholar
• Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch A-M, Kakavand H, Alexandrov LB, Burke H, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545:175–80. PMID: 28467829. doi:10.1038/nature22071.
   PubMed Web of Science ®Google Scholar
• Dillman RO. Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors? Hum Vaccin Immunother. 2017;13(3):528–32. PMID: 27808593. doi:10.1080/21645515.2016.1244149.
   PubMed Web of Science ®Google Scholar
• Lei X, Guan CW, Song Y, Wang H. The multifaceted role of CD146/MCAM in the promotion of melanoma progression. Cancer Cell Int. 2015;15(1):3. eCollection 2015 PMID:25685061. doi:10.1186/s12935-014-0147-z.
   PubMedGoogle Scholar
• Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, Butler PD, Yang GP, Joshua B, Kaplan MJ, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010;466(7302):133–37. PMID: 20596026. doi:10.1038/nature09161.
   PubMed Web of Science ®Google Scholar